

**Instructions for submitting changes and for reporting during the course of
a clinical trial****Content**

| | | |
|----|---|---|
| 1 | In general | 2 |
| 2 | Submission forms | 2 |
| 3 | Changes during the conduct of a clinical trial (amendments) (Art. 34 ClinO)..... | 3 |
| 4 | Protocol Amendments related to the use and/or safety of the IMP (Section 5 of the CTA dossier) | 4 |
| 5 | Changes to the pharmaceutical quality documentation (PQD) of the IMP (Section 7 of the CTA dossier) | 4 |
| 6 | Changes to Study Medication Labels (Section 9 of the CTA dossier) | 5 |
| 7 | Updated Investigator's Brochure (IB) (Section 6 of the CTA dossier) | 5 |
| 8 | Change of Sponsor / Sponsor Name or Address (Section 2 of the CTA dossier) | 5 |
| 9 | Change of Sponsor Swiss Representative/ Representative Name or Address (Section 2 of the CTA dossier) | 6 |
| 10 | Safety reporting in clinical trials of the categories B and C (Art. 37 ClinO) | 6 |
| 11 | Premature discontinuation / Trial interruption..... | 6 |
| 12 | End of the trial | 7 |
| 13 | Final clinical study report | 7 |

1 In general

These instructions concern changes and reporting related exclusively to **clinical trials of Category B and C**.

Points to consider:

Incomplete dossiers will not be processed but returned. Please only submit documents that are complete and ready for processing.

All documents (including submission forms) have to be submitted as **paper copy** (where requested as explained below in track change mode or with visible changes, otherwise as clean version) **AND** as an **electronic copy e.g. on CD-ROM** (clean version for all documents and where requested as explained below additionally in track change mode or with visible changes).

If not specified otherwise, all documents must be submitted as long as they cover the time period until study end in Switzerland is reached.

While a change is under evaluation it is not possible to assess another one. Therefore, a newly notified change will be put aside until we have sent you the answer to the previous one. The review period of 30 days will start at that moment.

2 Submission forms

The following **original signed forms** must be used:

A. Changes to a running trial according to chapters 3 to 9 of this document

- **Form BW101_10_004e_FO Submission of Changes to a Clinical Trial**
Title: *Submission of Changes to a Clinical Trial and Answer to Conditions*
- Available on our web page under www.swissmedic.ch > Licensing > Clinical trials on medicinal products > Submission of changes > Forms and checklists

B. Reporting related to a trial and trial completion according to chapters 10 to 13 of this document

- **Form BW101_10_005e_FO Reporting Related to a Clinical Trial**
Title: *Reporting Related to a Clinical Trial*
- Available on our web page under www.swissmedic.ch > Licensing > Clinical trials on medicinal products > Submission of changes > Forms and checklists

C. Answers to conditions made by Swissmedic

- **Form BW101_10_004e_FO Submission of Changes to a Clinical Trial**
Title: *Submission of Changes to a Clinical Trial and Answer to Conditions*
- Available on our web page under www.swissmedic.ch > Licensing > Clinical trials on medicinal products > Submission of changes > Forms and checklists

D. Change of sponsorship

- **Form BW101_10_017e_FO Change of sponsorship**
Title: *Change of Sponsorship*
- Available on our web page under www.swissmedic.ch > Licensing > Clinical trials on medicinal products > Submission of changes > Forms and checklists

E. Change of Swiss representative

- **Form BW101_10_019e_FO Change of Swiss Representative**
Title: *Change of Swiss representative*
- Available on our web page under www.swissmedic.ch > Licensing > Clinical trials on medicinal products > Submission of changes > Forms and checklists

F. SUSARS

- **CIOMS forms (international standard)** and
- **Form BW101_20_001e_FO Accompanying form for SUSARs**
Title: *Accompanying Form SUSAR*
- Available on our web page under www.swissmedic.ch > Licensing > Clinical trials on medicinal products > Safety measures in clinical trials > Instructions and forms
- **Please consult our information sheet *Safety Relating to Clinical Trials – Compulsory notification*** under www.swissmedic.ch > Licensing > Clinical trials on medicinal products > Safety measures in clinical trials.

IMPORTANT information on the above-listed topics A-C:

- A document related to several clinical trials can be submitted using a single submission form. **However, a separate form must be used for each sponsor representative.** The clinical trial(s) must be clearly identified with their Swissmedic reference numbers.
- Please **do not send any cover letter.**
If this cannot be avoided due to the necessity of providing relevant information which cannot be included in the submission form, please list this letter as a document in the form (S10 of form "Submission of Changes to a Clinical Trial and Answer to Conditions" / R1 of form "Reporting Related to a Clinical Trial").
- All documents related to the notified changes or reporting have to be listed on the submission form in the corresponding field. If several documents are submitted for the same section of the CTA dossier, additional lines must be added for the corresponding section of the CTA dossier. Incomplete or not correctly filled forms will not be accepted.
- The sponsor is sole responsible for the correct designation of the documents on the form and thus for a clear identification of the documents that have been submitted to Swissmedic for acknowledgement or approval of changes. Incorrect identification of the documents may lead to findings during an inspection.
- For submissions of changes, a letter will be issued by Swissmedic ("decision" letter in case of significant changes, acknowledgement letter in case of other changes).
For reporting, Swissmedic will send an acknowledgement by e-mail, with reference to the corresponding submission form.

3 Changes during the conduct of a clinical trial (amendments) (Art. 34 ClinO)

All changes in the documents as listed in ClinO Annex 4, 1.2 – 1.7 and 2.2. – 2.7 have to be submitted to Swissmedic.

Significant changes must be submitted to Swissmedic together with a rationale from the Sponsor (to be entered under point 2 on the form *Submission of Changes to a Clinical Trial and Answer to Conditions*). The amendments cannot be implemented before the approvals of both Swissmedic and the Ethics Committee have been obtained.

Exception: urgent safety measures may be implemented before Swissmedic approval.

The definition of significant changes that have to be submitted to Swissmedic is given in Art. 34 ClinO and below.

Other changes shall be sent to Swissmedic as soon as possible (Art. 34, para 5 ClinO).

4 Protocol Amendments related to the use and/or safety of the IMP **(Section 5 of the CTA dossier)**

All protocol amendments must be submitted to Swissmedic. The changes related to the use and/or safety of the IMP or any other significant modification according to art. 34 paragraph 3 ClinO must be approved by Swissmedic prior to implementation (exception: urgent safety measures). For all other changes (art. 34 paragraph 5 ClinO) Swissmedic will send an acknowledgement of receipt.

Protocol modifications must be documented in a summary of changes and the updated protocol version submitted in a **track change** (ideally a color print) mode or with visible changes.

5 Changes to the pharmaceutical quality documentation (PQD) of the IMP **(Section 7 of the CTA dossier)**

Changes to the PQD or the IMPD shall only be submitted if related to the clinical trial.

All changes to the PQD or IMPD related to the clinical trial have to be submitted to Swissmedic.

A guidance on the substantial changes that need to be submitted to Swissmedic can be found in the European guideline "Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (CHMP/QWP/185401/2004 chapter 8). All changes listed in chapter 8, including those mentioned as "not required" must be submitted to Swissmedic for approval.

Guidance for the submission of a change to the PQD:

1. Tabular overview of changes

A tabular overview **including all changes**, significant or not, has to be provided. This tabular overview of changes can be a separate document or it can be integrated in the amendment. If this table is integrated in the amended document, it must be printed separately for each trial involved.

Example:

| Amendment name, version, date | | | Significant? | |
|---|---|-------------------|--------------|----|
| Previous Document number | New Document number | Reason for change | yes | no |
| <u>Chapter xy</u> Previous information <i>Full text</i> | <u>Chapter xy</u> new information <i>Full text with changes in</i> - Bold and strike out Or - track change mode | Give rationale | | X |
| ... | ... | ... | | |

2. CD-Rom:

- Form *Submission of Changes to a Clinical Trial*
- Amended documents in Track Change Version, if available
- Amended documents Clean Version
- Tabular overview of changes if not already contained in the amended document itself.

3. *Paper Versions.*

- Form *Submission of Changes to a Clinical Trial*, signed by applicant
- **Full track change version** (color print) if available.
In case only a clean version can be submitted all changes have to be clearly visible in the tabular overview of changes.
If the amendment concerns **more than one trial**, only one printout has to be provided.
- **Tabular overview of changes.**
Please provide a copy of the overview for each trial concerned by the submission.

**6 Changes to Study Medication Labels
(Section 9 of the CTA dossier)**

Changes of the IMP-name have to be submitted to Swissmedic for approval. All other changes to the study label shall be submitted for information only.

**7 Updated Investigator's Brochure (IB)
(Section 6 of the CTA dossier)**

The updated IB needs to be submitted **until the final clinical study report is available**. The changes to the IB must be documented in a summary of changes **as shown in the model below** and the updated version shall be submitted **in track change** mode or with visible changes.

Moreover, it must be indicated if, and to what extent, the **risk/benefit analysis** of the trial substance has changed. Should any measures have been taken on the basis of the new analysis, these should also be described.

Model: summary of changes

| section | Old text | New text | Rational for change |
|---------------------|--|---|---------------------|
| 1.0 Change | Original text to be changed in this section. | Original New text to be changed in this section with visible changes. | Reason for changes |
| 1.1 New information | Original text | Original text... Added text | New information |
| 1.2 Deleted text | Original text to be deleted | Deleted text | Reason for deletion |

**8 Change of Sponsor / Sponsor Name or Address
(Section 2 of the CTA dossier)**

Swissmedic's authorisation to perform a clinical trial **cannot** be transferred from a sponsor to another one. **If a new sponsor takes over a clinical trial** that has already been authorised for another

sponsor, he must ask Swissmedic for a new authorisation. For this purpose, the new sponsor must complete the form *Change of Sponsorship* (www.swissmedic.ch) (including date and signature).

The completed form must be sent to Swissmedic **at least 30 days prior to the date of take-over** of the sponsorship. The submission must include a statement (signed and dated) of the previous sponsor that he gives up the sponsorship of the clinical trial.

In case of **change of sponsor name or address**, the form *Change of Sponsorship* needs to be submitted as described above.

For a change of sponsor or sponsor name or a change of sponsor address involving a **change of country**, Swissmedic will issue an authorisation for the new sponsor or sponsor with new name or address, respectively and withdraw the previous authorisation.

A change of sponsor **domicile within a country** will be acknowledged only by Email.

Trial documents that have to be modified due to the change of sponsorship / change of sponsor name or address (protocol, labels, etc.) must be sent to Swissmedic according to ClinO annex 4.

9 Change of Sponsor Swiss Representative/ Representative Name or Address (Section 2 of the CTA dossier)

If a **new sponsor representative** takes over responsibilities, Swissmedic must be informed.

For this purpose, the sponsor must complete the form *Change of Swiss Representative* (www.swissmedic.ch) (including date and signature).

The completed form must be sent to Swissmedic **at least 30 days prior to the date of change of sponsor representative**.

The same applies for **change of sponsor representative name or address**.

Swissmedic will confirm by e-mail that it has taken note of the change of sponsor representative / sponsor representative name or address.

10 Safety reporting in clinical trials of the categories B and C (Art. 37 ClinO)

Urgent safety and protective measures in clinical trials of the categories B and C must be taken immediately, without waiting approval by Swissmedic. They must be **reported within 7 days** to Swissmedic by the Sponsor.

Detailed information on safety measures including urgent safety measures, SUSARs or Annual Safety Report can be found on the Swissmedic website under "Safety measures in clinical trials".

11 Premature discontinuation / Trial interruption

The sponsor must report a premature discontinuation or interruption of a clinical trial to Swissmedic, stating the reasons for the discontinuation or interruption.

The reporting timeline is **15 days** (Art. 38 para. 2 ClinO). If a trial is stopped prematurely for safety-relevant reasons, Swissmedic must be informed within **7 days** (Art. 37 para. 1 ClinO).

A final clinical study report (further details below) must be submitted.

12 End of the trial

The end of the trial is considered to be the 'last subject last visit' of the last open centre in Switzerland, unless differently defined in the trial protocol. The sponsor must report the end of a clinical trial to Swissmedic.

The reporting timeline is **90 days** (Art. 38 para. 1 ClinO).

A final clinical study report (further details below) must be submitted.

For international trials, Swissmedic accepts the international end date of the trial as the reference date for submitting the final report. Therefore, In order to determine the time limit that will be applied, Swissmedic must also be informed (in addition to the date on which the trial ends in Switzerland) on the date of international trial end.

13 Final clinical study report

A final clinical study report on the whole study must be submitted in line with Art 38 para. 5 of the ClinO within **1 year** of trial end or premature discontinuation.

Swissmedic has not published any guidelines on the formal requirements for the final report; however the ICH E3 guidelines (Structure and content of clinical study reports) should be followed. The final report should adequately summarize the data collected in the clinical trial.

The complete report without annexes (corresponding to chapters 1-15 of ICH E3) and a synopsis shall be submitted on CD and the synopsis shall additionally be submitted as a hard copy.

For international clinical trials which did not include subjects in Switzerland, no submission of the report or a synopsis is needed.

In the case of international trials that last longer than the participation of the Swiss centres, the final report should be submitted within **1 year of the end of the international trial** (Art. 38 para. 5 ClinO).

Change history

| Version | Valid and binding as of: | Modified without version change | Description, comments (by author) | Author's initials |
|---------|--------------------------|---------------------------------|--|-------------------|
| 04 | 05.05.17 | | Clarifications for submission requirements | hch, jaf |
| 03 | 15.01.17 | | New submission requirements with introduction of two new submission forms, clarifications | hch, gav, jaf |
| 02 | 25.01.16 | | New order of chapters for changes and reporting clarifications and corrections | hch |
| 01 | 26.06.15 | | Document belongs to new process (new QM-Ident) Old: BW101_20_001e_AL New: BW101_10_003_AA Clarification concerning submission of some changes / Introduction of the new form Change of Swiss Representative | hch |
| 12 | 30.04.15 | | Inclusion of guidance for the submission of a change to the pharmaceutical quality documentation and to the Investigator's Brochure / inclusion of information on change of sponsor and change of sponsor representative / clarifications for Clinical Study Report | hch |

| | | | | |
|----|----------|----------|--|------------|
| 11 | 27.11.14 | | Clarifications of submission requirements | hch |
| | | 30.07.14 | New change history inserted in the document, dropdown field inserted in the header | wis |